Quince Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 61.47 | -100% | -11.91 | -100% |
| P/S |
|
0 | 33.58 | -100% |
|
|
| P/BV |
|
0.4989 | 4.79 | -89.59% |
|
|
| P/FCF |
|
-2.41 | 60.06 | -104.01% |
|
|
| Ev/Ebitda |
|
-1.46 | -17.26 | -91.54% |
|
|
| Ev/S |
|
0 | 22.49 | -100% |
|
|
| Ev/FCF |
|
-1.92 | 67.63 | -102.85% |
|
|
| E/P |
|
-0.7069 | 0.0168 | -4297.22% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | -12.31 | -100% | 0 | 0% |
| ROE |
|
-36.89 | 9.39 | -492.78% |
|
|
| ROA |
|
-17.42 | 0.1519 | -11563.83% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
0 | -25.64 | -100% |
|
|
| ROCE |
|
-28.96 | 14.76 | -296.23% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.5548 | -3.68 | -84.92% | -0.3146 | +76.34% |
| Nеt Debt/Ebitda |
|
0.2853 | -4.07 | -107.02% |
|
|
| Debt/Ratio |
|
0.0749 | 0.199 | -62.38% |
|
|
| Debt/Equity |
|
34.33 | 1.67 | 1961.95% |
|
|
| Debt/Net Income |
|
-0.4299 | 10.34 | -104.16% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5399 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2331 | -100% |
|
|
| Average dividend growth |
|
0 | 1.07 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4916 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.32 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5399 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | 76.2 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
-15.47 | 44.75 | -134.57% | ||
| Growth impulse Net Income in 5 years |
|
-14.7 | -15.36 | -4.3% | ||
| Growth impulse FCF in 5 years |
|
-44.64 | -9.39 | 375.4% | ||
| Growth impulse EPS in 5 years |
|
-56.4 | -84.03 | -32.88% |
IP Score
2.35/10
